Immatics NV
For the period ended May 13, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
May 13, 2025 · Filed May 13, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · 3. Segment information
- Segment information
The Group manages its operations as a single segment for the purpose of assessing performance and making operating decisions. The Group’s focus is on the research and development of T cell redirecting immunotherapies for the treatment of cancer. The Chief Executive Officer is the chief operating decision maker who regularly reviews the consolidated operating results and makes decisions about the allocation of the Group’s resources.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.